z-logo
open-access-imgOpen Access
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Author(s) -
Sabrina Pagai,
Eric A. Macklin,
Suzanne Hendrix,
James Berry,
Michael A. Elliott,
Samuel Maiser,
Chafic Karam,
James B. Caress,
Margaret Owegi,
Adam Quick,
James Wymer,
Stephen A. Goutman,
Daragh Heitzman,
Terry HeimanPatterson,
Carlayne E. Jackson,
Colin Quinn,
Jeffrey D. Rothstein,
Edward J. Kasarskis,
Jonathan Katz,
Liberty Jenkins,
Shafeeq Ladha,
Jonathan Mill,
Stephen N. Scelsa,
Tuan Vu,
Christi. Fournier,
Jonathan D. Glass,
Kristin Johnson,
Andrea Swenson,
Namita Goyal,
Gary L. Pattee,
Patricia L. Andres,
Suma Babu,
Marianne Chase,
Derek D’Agostino,
Samuel P. Dickson,
Noel Ellison,
Meghan Hall,
Kent Hendrix,
Gale Kittle,
Michelle McGovern,
Joseph Ostrow,
Lindsay Pothier,
Rebecca Randall,
Jeremy M. Shefner,
Alexander Sherman,
Eric Tustison,
Prasha Vigneswaran,
Jason Walker,
Hong Yu,
James Chan,
Janet Wittes,
Joshua Cohen,
Justin Klee,
Kent Leslie,
Rudolph E. Tanzi,
Walter Gilbert,
Patrick Yeramian,
David Schoenfeld,
Merit Cudkowicz
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1916945
Subject(s) - phenylbutyrate , amyotrophic lateral sclerosis , medicine , chemistry , disease
Sodium phenylbutyrate and taurursodiol have been found to reduce neuronal death in experimental models. The efficacy and safety of a combination of the two compounds in persons with amyotrophic lateral sclerosis (ALS) are not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom